AI Summary
Theravance Biopharma has agreed to a cash purchase by Zymeworks at $17 per share, valuing the company around $929 million and including a CVR for 80% of future ampreloxetine proceeds. The deal follows a comprehensive strategic review and targets closing in the second half of 2026, subject to approvals. The CVR adds optional upside if monetization opportunities materialize, potentially enhancing value beyond the cash offer.
Sentiment Rationale
Cash offer at a premium creates a near-term price floor; CVR adds optional upside tied to future assets; higher likelihood TBPH trades toward $17 pre-close, barring deal disruption.
Trading Thesis
Bullish near-term on a $17 cash offer; upside potential from the CVR if ampreloxetine monetization occurs, with uncertainty until close in H2 2026.
Market-Moving
- Cash offer sets a floor near $17/ TBPH share ahead of closing.
- CVR provides optional upside linked to ampreloxetine monetization over 10 years.
- Closing risk includes shareholder and regulatory approvals and customary conditions.
- Delisting risk post-completion may affect liquidity for TBPH holders.
Key Facts
- Theravance Biopharma to be acquired by Zymeworks for $17 per share.
- Equity value around $929 million, plus CVR for 80% of ampreloxetine proceeds.
- Strategic Review Committee and Board approved; closing targeted for H2 2026.
- TRELEGY royalty monetization yielded $225 million in 2025, underpinning value.
- Premiums: 22% vs March 3, 2026 close; 10% vs VWAP since that date.
Companies Mentioned
- Theravance Biopharma (TBPH): Subject of the deal; investors receive cash and CVR; potential delisting after close.
- Zymeworks (ZYME): Buyer; pays cash and CVR; strategy includes monetizing ampreloxetine via a CVR.
- Viatris (VTRS): TRELEGY royalty partner referenced; potential implications for royalties and future monetization.
M&A
M&A: Corporate deal driving immediate value realization with optional upside from CVR; influences TBPH's near-term price and post-close liquidity considerations.